<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-id journal-id-type="pmc">brjcancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">9374387</article-id>
      <article-id pub-id-type="pmc">2228140</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gillespie</surname>
            <given-names>A. M.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lorigan</surname>
            <given-names>P. C.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Radstone</surname>
            <given-names>C. R.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Waterhouse</surname>
            <given-names>J. C.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coleman</surname>
            <given-names>R. E.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hancock</surname>
            <given-names>B. W.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>Sheffield Supraregional Trophoblastic Disease Screening and Treatment Centre, Yorkshire Cancer Research Campaign Department of Clinical Oncology, Weston Park Hospital, UK.</aff>
      <pub-date pub-type="ppub">
        <year>1997</year>
      </pub-date>
      <volume>76</volume>
      <issue>10</issue>
      <fpage>1382</fpage>
      <lpage>1386</lpage>
      <abstract>
        <p>The Sheffield Trophoblastic Disease Centre treats about 25 patients with persistent trophoblastic disease each year. A total of 75% of patients are classified as low risk according to the Charing Cross Hospital prognostic scoring system and receive methotrexate (MTX) 50 mg, i.m., on days 1, 3, 5, 7 with folinic acid 7.5 mg orally 24 h after each methotrexate injection. There is a 7-day rest between treatment cycles. Remission is achieved in 85% of cases. Approximately 20% of patients experienced pleuritic chest pain and dyspnoea. We have evaluated prospectively lung function in 16 low-risk patients receiving methotrexate. All patients had pulmonary function tests [spirometry-forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEFR), and transfer factor - TLCO, kCO] performed before and after completed treatment. A mean of 7.5 cycles of MTX were administered (range 4-11). There was a significant reduction in the mean TLCO (mean pre/post 8.15/7.38 mmol min-1 kPa-1, P = 0.01), but there were no other statistically significant changes. Three patients experienced respiratory symptoms and were found to have a 39%, 28%, and 11% reduction in TLCO from baseline, improving on follow up to pretreatment levels. Low-dose MTX is an effective therapy but may cause troublesome pulmonary toxicity.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <supplementary-material content-type="scanned-pages">
      <graphic xlink:href="brjcancer00174-0132.tif" xlink:title="scanned-page" xlink:role="1382" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00174-0133.tif" xlink:title="scanned-page" xlink:role="1383" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00174-0134.tif" xlink:title="scanned-page" xlink:role="1384" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00174-0135.tif" xlink:title="scanned-page" xlink:role="1385" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00174-0136.tif" xlink:title="scanned-page" xlink:role="1386" mimetype="image" mime-subtype="tiff"/>
    </supplementary-material>
  </body>
</article>
</pmc-articleset>
